Lupin has announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc (LPI) has received tentative approval for the company`s Abbreviated New Drug Application (ANDA) for Eszopiclone tablets in strength of 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA).
Lupin`s Eszopiclone tablets are the AB-rated generic equivalent of Sepracor`s LUNESTA tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the twelve months ended December 2009, based on IMS Health sales data.
Source :www.biginfotech.in
Lupin`s Eszopiclone tablets are the AB-rated generic equivalent of Sepracor`s LUNESTA tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the twelve months ended December 2009, based on IMS Health sales data.
Source :www.biginfotech.in
No comments:
Post a Comment